drugset / Trial / NCT03982303
Phase I Study of Hemay102 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial was a single-center, open-label, dose-increasing Phase I clinical study with subjects enrolled in patients with advanced solid tumors who failed standard treatment or who were unable to receive effective treatment. The trial is divided into two stages: dose escalation and dose extension.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hemay102 | Unknown | 5 mg/m2 | Intravenous |
| Subject | Hemay102 | Unknown | 10 mg/m2 | Intravenous |
| Subject | Hemay102 | Unknown | 20 mg/m2 | Intravenous |
| Subject | Hemay102 | Unknown | 40 mg/m2 | Intravenous |
| Subject | Hemay102 | Unknown | 60 mg/m2 | Intravenous |
| Subject | Hemay102 | Unknown | 90 mg/m2 | Intravenous |
| Subject | Hemay102 | Unknown | 120 mg/m2 | Intravenous |
Indications
No indication recorded.